- Home
- FERA vs MRVI Comparison
FERA vs MRVI Comparison
Compare FERA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- MRVI
- Stock Information
- Founded
- FERA 2024
- MRVI 2014
- Country
- FERA Cayman Islands
- MRVI United States
- Employees
- FERA N/A
- MRVI 560
- Industry
- FERA
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- FERA
- MRVI Health Care
- Exchange
- FERA Nasdaq
- MRVI Nasdaq
- Market Cap
- FERA 317.4M
- MRVI 350.1M
- IPO Year
- FERA 2025
- MRVI 2020
- Fundamental
- Price
- FERA $10.13
- MRVI $2.42
- Analyst Decision
- FERA
- MRVI Hold
- Analyst Count
- FERA 0
- MRVI 10
- Target Price
- FERA N/A
- MRVI $5.84
- AVG Volume (30 Days)
- FERA 3.0
- MRVI 1.5M
- Earning Date
- FERA 01-01-0001
- MRVI 08-11-2025
- Dividend Yield
- FERA N/A
- MRVI N/A
- EPS Growth
- FERA N/A
- MRVI N/A
- EPS
- FERA N/A
- MRVI N/A
- Revenue
- FERA N/A
- MRVI $219,830,000.00
- Revenue This Year
- FERA N/A
- MRVI N/A
- Revenue Next Year
- FERA N/A
- MRVI $7.23
- P/E Ratio
- FERA N/A
- MRVI N/A
- Revenue Growth
- FERA N/A
- MRVI N/A
- 52 Week Low
- FERA $10.00
- MRVI $1.67
- 52 Week High
- FERA $10.60
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- MRVI 49.60
- Support Level
- FERA N/A
- MRVI $2.28
- Resistance Level
- FERA N/A
- MRVI $2.47
- Average True Range (ATR)
- FERA 0.00
- MRVI 0.14
- MACD
- FERA 0.00
- MRVI -0.01
- Stochastic Oscillator
- FERA 0.00
- MRVI 27.45
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.